ATXI - שווי שוק לנפח מכירות Avenue Therapeutics Inc.

Avenue Therapeutics possesses the prospect of premium pricing power driven by its safe drug portfolio. On GURU.Markets, the company's rolling P/S ratio reflects a market valuation where the mark characterizes this parameter. The business relies on the development of non-addictive IV Tramadol for clinics, while an intensive R&D pipeline focuses on molecules targeting tremors and acute nervous system conditions.
פילוחים אנליטיים של חברת Avenue Therapeutics Inc (ATXI)

The ratio of market capitalization to annual revenue measures the premium the market is willing to pay per unit of operating income, reflecting the level of confidence in future cash flows. For Avenue Therapeutics (ATXI), which is in the early stages of CNS development, the company's average P/S reflects a speculative valuation of clinical phase expectations, where sharp fluctuations on the chart signal the risk of overpaying at peaks.